Scholarlink

<p>Despite well-recognized biological heterogeneity, osteosarcoma has been treated as a single disease for over four decades with minimal improvement in survival. Clinical features are inadequate for risk stratification, and no molecular classifiers guide therapy. An international working group evaluated candidate prognostic biomarkers for clinical translation. Pre-treatment circulating tumor DNA is positioned for clinical implementation, while additional classifiers warrant prospective validation. This work establishes a path to risk-adapted, biologically informed treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An international framework for clinical translation of molecular classifiers in osteosarcoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Amanda E. Marinoff,
  • Michaela Nathrath,
  • David S. Shulman,
  • Sarah B. Whittle,
  • Jovana Pavisic,
  • Dimitrios Spentzos,
  • Catherine M. Albert,
  • Joshua O. Nash,
  • Adam Shlien,
  • Isidro Cortés-Ciriano,
  • Antonin Marchais,
  • Eunice López-Fuentes,
  • Christina Curtis,
  • E. Alejandro Sweet-Cordero,
  • Richard Gorlick,
  • Natalie DelRocco,
  • Rashmi Chugh,
  • William D. Tap,
  • Adrienne M. Flanagan,
  • Nathalie Gaspar,
  • Brian D. Crompton,
  • Damon R. Reed,
  • Katherine A. Janeway,
  • Patrick J. Grohar,
  • J. Andrew Livingston,
  • Ryan D. Roberts

摘要

Despite well-recognized biological heterogeneity, osteosarcoma has been treated as a single disease for over four decades with minimal improvement in survival. Clinical features are inadequate for risk stratification, and no molecular classifiers guide therapy. An international working group evaluated candidate prognostic biomarkers for clinical translation. Pre-treatment circulating tumor DNA is positioned for clinical implementation, while additional classifiers warrant prospective validation. This work establishes a path to risk-adapted, biologically informed treatment.